ATR and mature T-cell and NK-cell non-Hodgkin lymphoma: Various ATR inhibitors are well‐tolerated in the clinic (Dillon et al, 2019; Yap et al, 2020, 2021) and thus could be a readily translatable treatment for PTCL.